GHK-Cu and Progesterone HRT Interaction: What You Need to Know

Why This Combination Comes Up

Women on progesterone-based hormone replacement therapy increasingly ask about adding GHK-Cu for skin repair, wound healing, or anti-aging purposes. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that declines with age, dropping from approximately 200 ng/mL in plasma at age 20 to roughly 80 ng/mL by age 60 [1]. Progesterone, prescribed as oral micronized progesterone (Prometrium) or compounded formulations, is a standard component of combined HRT for endometrial protection in women with an intact uterus [2].

The Clinical Scenario

The typical patient asking this question is a perimenopausal or postmenopausal woman taking 100 to 200 mg oral micronized progesterone nightly, who wants to add topical or injectable GHK-Cu for collagen support. Because GHK-Cu is available through 503A compounding pharmacies and has no FDA-approved drug label, formal interaction data does not exist in standard DDI databases like Lexicomp or Clinical Pharmacology.

What the Databases Show

Neither Lexicomp, Micromedex, nor the FDA Adverse Event Reporting System (FAERS) contain interaction entries pairing GHK-Cu with progesterone. This absence reflects a data gap rather than confirmed safety. The Endocrine Society's 2022 clinical practice guideline on menopausal HRT does not address peptide co-administration [3].

Pharmacokinetic Analysis: Minimal Overlap

The pharmacokinetic profiles of these two agents diverge significantly. GHK-Cu is a small tripeptide (molecular weight 403.9 Da) broken down by plasma peptidases into its amino acid components and free copper ions. It does not undergo hepatic phase I oxidation through cytochrome P450 enzymes [4].

Progesterone's CYP Pathway

Oral micronized progesterone is absorbed from the GI tract with extensive first-pass hepatic metabolism. CYP3A4 is the primary enzyme, with CYP2C19 contributing to a lesser degree. The FDA-approved Prometrium label lists known CYP3A4 inhibitors (ketoconazole, erythromycin) as agents that may increase progesterone exposure [2]. GHK-Cu has shown no CYP3A4 inhibition or induction in available preclinical data [4].

P-glycoprotein and Transporter Effects

Progesterone is a substrate of P-glycoprotein (P-gp), though this transporter plays a secondary role compared to CYP-mediated clearance. No published study has evaluated GHK-Cu's effect on P-gp transport activity. Given GHK-Cu's peptide structure and rapid hydrolysis in plasma, significant P-gp modulation is unlikely, but this remains unconfirmed [5].

Protein Binding Considerations

Progesterone is 96 to 99% bound to plasma proteins, primarily albumin and cortisol-binding globulin. GHK-Cu circulates briefly before degradation and does not compete for protein binding sites at pharmacologically relevant concentrations. Displacement interactions are not a credible concern with this combination.

Pharmacodynamic Overlap: Sedation and CNS Effects

The one area of genuine clinical relevance is pharmacodynamic overlap in central nervous system sedation. Oral micronized progesterone produces dose-dependent drowsiness through its neuroactive metabolite allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [6]. This is why prescribers instruct patients to take Prometrium at bedtime.

GHK-Cu and Neurological Activity

GHK-Cu has demonstrated neuroprotective and anti-anxiety properties in animal models. A 2018 gene expression analysis showed that GHK modulates several genes associated with the nervous system, including those involved in GABA signaling pathways [7]. Whether systemic GHK-Cu administration in humans produces clinically meaningful sedation is unknown. Topical GHK-Cu at concentrations used in skincare (0.01 to 1%) reaches negligible systemic levels, making CNS effects from topical use implausible.

When Sedation Overlap Matters

For patients using injectable or oral GHK-Cu (compounded preparations with higher systemic exposure), the theoretical additive sedation with bedtime progesterone deserves consideration. No published case report documents this interaction. A reasonable precaution: patients starting systemic GHK-Cu while on oral progesterone should avoid combining both doses at the same time of day until they understand their individual response.

Copper Homeostasis: A Nuanced Concern

Every molecule of GHK-Cu delivers one atom of copper (Cu²⁺). This raises questions about copper accumulation, especially in patients on long-term therapy.

Normal Copper Physiology

The adult body contains 50 to 120 mg of total copper. Dietary intake averages 0.6 to 1.6 mg per day, and the recommended dietary allowance is 0.9 mg daily for adults [8]. Copper homeostasis is tightly regulated by hepatic excretion into bile, with ceruloplasmin serving as the primary plasma copper carrier.

GHK-Cu Copper Load

A typical compounded GHK-Cu injection delivers 1 to 5 mg of the peptide complex per dose. At a molecular weight of 403.9 Da with one copper atom (63.5 Da), the copper content per milligram of GHK-Cu is approximately 0.157 mg. A 5 mg injection therefore delivers about 0.79 mg of copper, comparable to a day's dietary intake. Topical preparations deliver far less systemically.

Progesterone's Effect on Copper

This is where the interaction becomes clinically interesting. Estrogen is well documented to raise serum copper and ceruloplasmin levels. Progesterone alone does not produce this effect, but many HRT regimens combine estradiol with progesterone. Women on combined estrogen-progesterone HRT may already have elevated baseline copper levels [9]. Adding exogenous copper through GHK-Cu in this context warrants monitoring. A serum copper and ceruloplasmin panel at baseline and every 12 weeks is prudent for patients on both systemic GHK-Cu and combined HRT.

Wilson Disease and Copper Sensitivity

Patients with Wilson disease or heterozygous ATP7B mutations should not use GHK-Cu without hepatology clearance. This applies regardless of progesterone use but becomes more relevant in the HRT population because estrogen-driven ceruloplasmin elevation can mask early copper overload on standard lab panels [10].

Route of Administration Changes the Risk Profile

Not all GHK-Cu exposure is equal. The route matters significantly for this interaction assessment.

Topical GHK-Cu

Topical copper peptide serums (0.01 to 1% GHK-Cu) produce minimal systemic absorption. A 2020 pharmacokinetic study of topical copper peptides found plasma copper increases within the margin of assay variability [4]. For patients using topical GHK-Cu alongside oral progesterone, the interaction risk is negligible. No monitoring beyond standard HRT labs is needed.

Subcutaneous Injectable GHK-Cu

Compounded subcutaneous GHK-Cu (typically 1 to 5 mg daily or several times per week) produces measurable systemic exposure. This is the route where both the sedation overlap and copper load concerns apply. Patients on this route with concurrent progesterone HRT should have baseline and periodic copper studies.

Oral GHK-Cu Supplements

Oral copper peptide supplements exist but face significant degradation in gastric acid. Bioavailability is poorly characterized. The interaction profile for oral GHK-Cu with progesterone is the least well-defined of any route.

Monitoring Recommendations

A structured monitoring approach reduces the residual uncertainty around this combination.

Baseline Labs Before Starting GHK-Cu

For patients already on progesterone HRT who plan to start systemic GHK-Cu, the following baseline labs are recommended:

• Serum copper (normal range 70 to 150 mcg/dL)
• Ceruloplasmin (normal range 20 to 35 mg/dL)
• Hepatic function panel (AST, ALT, alkaline phosphatase)
• CBC with differential

Ongoing Monitoring Schedule

Repeat serum copper and ceruloplasmin at 6 weeks and then every 12 weeks for the first year. Hepatic function should be rechecked at 12 weeks. If serum copper exceeds 150 mcg/dL or free copper (calculated as total copper minus ceruloplasmin-bound copper) rises above 15 mcg/dL, GHK-Cu dose reduction or discontinuation should be discussed [8].

Signs to Report

Patients should be counseled to report new or worsening fatigue, unusual daytime drowsiness (beyond what they attribute to progesterone), abdominal pain, dark urine, or Kayser-Fleischer ring appearance (brownish discoloration at the corneal periphery, though this is rare and late-stage).

Dose Adjustment Guidance

No dose adjustment to either agent is required based on current evidence. The 2022 Endocrine Society HRT guidelines recommend maintaining progesterone at the lowest effective dose for endometrial protection (typically 100 mg nightly for sequential or 100 to 200 mg for continuous-combined regimens) [3]. GHK-Cu dosing should follow the compounding prescriber's protocol, which typically ranges from 1 to 5 mg subcutaneously.

If a patient reports significant next-day sedation after starting GHK-Cu while on bedtime progesterone, consider separating administration times (GHK-Cu in the morning, progesterone at bedtime) before reducing either dose.

Patient Counseling Points

Clear communication reduces anxiety and improves adherence in patients combining these agents.

What to Tell Patients

First, reassure the patient that no published interaction between GHK-Cu and progesterone HRT has been reported. Second, explain that the monitoring labs are precautionary, not reactive to a known problem. Third, emphasize that topical GHK-Cu products (serums, creams) pose essentially no interaction risk with progesterone.

Red Flags for Immediate Contact

Instruct patients to contact their prescriber immediately if they experience jaundice, severe unexplained fatigue, or neurological symptoms such as tremor or difficulty with coordination. These could indicate copper toxicity, which is rare but serious [10].

Documentation Note for Prescribers

Because GHK-Cu is not in standard DDI databases, the interaction assessment should be documented in the patient's chart as a clinical pharmacology review rather than a database-generated alert. Note the date of review, the routes of administration, and the monitoring plan.

The Bottom Line on Combined Use

The GHK-Cu and progesterone HRT combination carries a low theoretical risk profile. No pharmacokinetic interaction has been identified. The pharmacodynamic concern (additive sedation) applies only to systemic GHK-Cu and can be managed by separating administration times. Copper homeostasis monitoring is warranted for systemic GHK-Cu use in any patient, and the concurrent use of estrogen-containing HRT makes this monitoring slightly more important. For patients using topical GHK-Cu only, no special precautions beyond standard HRT monitoring are needed. Baseline serum copper should be checked before initiating systemic GHK-Cu in any patient on combined HRT, with repeat testing at 6 weeks and quarterly thereafter.